DocWire News Editors

DocwireNews

Researchers have developed diabetes mellitus (DM)-specific risk score that demonstrates efficacy in assessing the risk of cardiovascular disease (CVD) in diabetic patients.&ldquo;Existing CVD risk scores used in diabetes mellitus (DM) patients may be outdated, derived from single or clinical trial cohort, or designed for one endpoint,&rdquo; the researchers said in an abstract, the results of which were presented at the American Heart Association 2019 Scientific Sessions in Philadelphia. &ldquo;We aimed to develop a set of risk scores for total CVD and its separate components of coronary heart disease (CHD), heart failure (HF) and stroke.&rdquo;The authors pooled 4,183 CVD-free adults with DM (aged 30-86, 45% male, 45% Black) from five US population-based cohorts: Atherosclerosis Risk in Communities Study (ARIC), the Multi-Ethnic Study of Atherosclerosis (MESA), the Coronary Artery Risk Development in Young Adults Study, the Jackson Heart Study, and the Framingham Heart Study Offspring cohorts. Subsequently, they developed 10-year risk scores for total CVD, which included myocardial infarction, cardiac revascularization, stroke, HF, peripheral artery disease, and CVD health, as well as individual components of coronary heart disease (CHD), HF, and stroke.The results of the study showed that the average predicted 10-year risks were 21.8% for CVD, 12.7% for CHD, 9.8% for HF, and 5.8% for stroke. The risk scores were deemed to have a strong internal discrimination and calibration (c-statistics: 0.70-0.76; calibration slopes: 1.03-1.17 comparing observed vs. predicted risk). In the ACCORD cohort, the new scores showed superior performance over FRS and UKPDS (c-statistics 0.62-0.71 vs. 0.55-0.60), with net reclassification improvement between 0.03 and 0.26.&ldquo;Our DM-specific CVD risk score based on pooled-data from five cohorts demonstrated good predictive performance and may be useful for assessing the risk of CVD and its components in US adults with DM,&rdquo; the authors concluded.

Katie Kosko

Study Links Body Composition to Trastuzumab Deruxtecan Dosing, Toxicity

HER2 Breast Cancer

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Latest News

New Diabetes-Specific CVD Risk Score: Development and Validation

AHA 2019

Researchers have developed diabetes mellitus (DM)-specific risk score that demonstrates efficacy in assessing the risk of cardiovascular disease (CVD) in diabetic patients. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe